Pipeline / BPC-305

immunology · small molecule

BPC-305 — Systemic lupus erythematosus

A selective TYK2 degrader designed to silence interferon-alpha signaling in autoimmune disease. Preclinical development is ongoing with IND-enabling studies planned.

preclinical Target: Tyrosine kinase 2 (TYK2) Sample data

Investigational candidate. BPC-305 has not been approved by any regulatory authority.

Mechanism of action

How the molecule works.

BPC-305 tags TYK2 for proteasomal degradation via a molecular glue, removing the signaling scaffold required for interferon-alpha receptor signal transduction.

Milestones

Program timeline.

  1. 2023 Hit-to-lead done
  2. 2024 Lead optimization done
  3. 2025 Candidate nomination current
  4. 2026 IND-enabling studies planned
  5. 2027 IND filing planned

Publications

3 related publications.

  • Nature Chemical Biology 2024

    Targeted degradation of TYK2 suppresses interferon-alpha signaling in autoimmune models

    Raman A, Becker T, Fischer L, et al.

    Discovery and preclinical profiling of BPC-305, a selective TYK2 degrader that silences interferon-alpha receptor signaling.

    DOI: 10.1038/s41589.[sample]
  • Cell Chemical Biology 2022

    A structure-guided platform for the discovery of selective kinase inhibitors

    Raman A, Fischer L, Becker T, et al.

    An overview of the structure-guided discovery platform underlying the BPC-101 and BPC-305 programs.

    DOI: 10.1016/j.chembiol.[sample]
  • PNAS 2022

    Antibody and antibody-drug conjugate discovery using engineered Fc libraries

    Hoffmann P, Shah N, Watanabe K, et al.

    Description of the Fc engineering library used to discover BPC-203 and to assemble the BPC-402 linker-payload.

    DOI: 10.1073/pnas.[sample]
Back to pipeline Contact about this program